References
- Allen T.M., Cheng W.W., Hare J.I., Laginha K.M.: Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer. Anticancer Agents Med Chem 2008, 6, 513–523, doi: 10.2174/187152006778699121.
- Allen T.M., Cullis P.R.: Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013, 65, 36–48, doi: 10.1016/j.addr.2012.09.037.
- Anderson R.L., Balasas T., Callaghan J., Coombes R.C., Evans J., Hall J., Kinrade S., Jones D., Jones P., Jones R., Marshall J., Panico M.B., Shaw J.A., Steeg P., Sullivan M., Warwick T., Westwell A.D., Ritchie J.W.A.: A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol 2019, 16, 185–204, doi: 10.1038/s41571-018-0134-8.
- Augustine R., Alhussain H., Hasan A., Ahmed M.B., Yalcin H.C., Moustafa A.E.: A novel in ovo model to study cancer metastasis using chicken embryos and GFP expressing cancer cells. Bosn J Basic Med Sci 2020, 20, 140–148. doi: 10.17305/bjbms.2019.4372.
- Børresen B., Hansen A.E., Kjær A., Andresen T.L., Kristensen A.T.: Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals. Vet Comp Oncol 2018, 16, E1–E15, doi: 10.1111/vco.12342.
- Boston S.E., Ehrhart N.P., Dernell W.S., Lafferty M., Withrowet S.J.: Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004). J Am Vet Med Assoc 2006, 228, 1905–1908, doi: 10.2460/javma.228.12.1905.
- Eom Y.W., Kim M.A., Park S.S., Goo M.J., Kwon H.J., Sohn S., Kim W.-H., Yoon G., Choi K.S.: Two distinct modes of cell death induced by doxorubicin: Apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005, 24, 4765–4777, doi: 10.1038/sj.onc.1208627.
- European Medicines Agency: EMA/635791/2019/EMEA/H/C/000089 Caelyx pegylated liposomal European public assessment report (EPAR) – Medicine overview. EMA, Amsterdam, 2019, https://www.ema.europa.eu/en/documents/product-information/caelyx-pegylated-liposomal-epar-product-information_en.pdf
- Haghiralsadat F., Amoabediny G., Sheikhha M.H., Forouzanfar T., Helder M.N., Zandieh-Doulabi B.: A novel approach on drug delivery: Investigation of a new nano-formulation of liposomal doxorubicin and biological evaluation of entrapped doxorubicin on various osteosarcoma cell lines. Cell J 2017, 19, 55–64, doi: 10.22074/cellj.2017.4502.
- Janssen L.M.E., Ramsay E.E., Logsdon C.D., Overwijk W.W.: The immune system in cancer metastasis: Friend or foe? J Immunother Cancer 2017, 5, 1–14, doi: 10.1186/s40425-017-0283-9.
- Jonkman J.E.N., Cathcart J.A., Xu F., Bartolini M.E., Amon J.E., Stevens K.M., Colarussoet P.: An introduction to the wound healing assay using live-cell microscopy. Cell Adhes Migr 2014, 8, 440–451. doi: 10.4161/cam.36224.
- Khan S., Pathak P., Vasudevan S., Nayak D.: Non-invasive photoacoustic screening of blood vasculature during anti-angiogenesis using CAM assay. OSA Contin 2021, 4, 2821, doi: 10.1364/osac.432084.
- Kim Y., Williams K.C., Gavin C.T., Jardine E., Chambers A.F., Leong H.S.: Quantification of cancer cell extravasation in vivo. Nat Protoc 2016, 11, 937–948, doi: 10.1038/nprot.2016.050.
- Lou N, Wang Y., Sun D., Zhao J., Wang Y., Gao Z.: Isolation of stem-like cells from human MG-63 osteosarcoma cells using limiting dilution in combination with vincristine selection. Indian J Biochem Biophys 2010, 47, 340–347.
- Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., Groom A.C.: Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998, 153, 865–873, doi: 10.1016/S0002-9440(10)65628-3.
- Małek A., Taciak B., Sobczak K., Grzelak A., Wójcik M., Mieczkowski J., Lechowski R., Zabielska-Koczywąs K.A.: Enhanced cytotoxic effect of doxorubicin conjugated to glutathione-stabilized gold nanoparticles in canine osteosarcoma—in vitro studies. Molecules 2021, 26, 3487, doi: 10.3390/molecules26123487.
- Mohanty A., Uthaman S., Park I.K.: Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy. Molecules 2020, 25, 4377, doi: 10.3390/molecules25194377.
- Pistritto G., Trisciuoglio D., Ceci C., Garufi A., D’Orazi G.: Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging 2016, 8, 603–619, doi: 10.18632/aging.100934.
- Salzberg M., Thürlimann B., Hasler U., Delmore G.C., von Rohr A.D., Thürlimann A. Ruhstaller T.B., Stopatschinskaja S.E., von Moos R.: Pegylated liposomal doxorubicin (Caelyx®) in metastatic breast cancer: A community-based observation study. Oncology 2008, 72, 147–151, doi: 10.1159/000112731.
- Selvarajah G.T., Kirpensteijn J.: Prognostic and predictive biomarkers of canine osteosarcoma. Vet J 2010, 18, 528–35, doi: 10.1016/j.tvjl.2010.04.010.
- Skorupski K.A., Uhl J.M., Szivek A., Frazier S.D.A., Rebhun R.B., Rodriguez Jr C.O.: Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial. Vet Comp Oncol 2016, 14, 81–87, doi: 10.1111/vco.12069.
- Straw R.C., Withrow S.J., Powers B.E.: Management of canine appendicular osteosarcoma. Vet Clin North Am Small Anim Pract 1990, 20, 1141–1161, doi: 10.1016/S0195-5616(90)50089-3.
- Szewczyk M., Lechowski R., Zabielska K.: What do we know about canine osteosarcoma treatment? – review. Vet Res Commun 2015, 39, 61–67, doi: 10.1007/s11259-014-9623-0.
- Taghipour M., Vand A.A., Rezaei A., Karimi G.H.: Application of Artificial Neural Network for Modeling and Prediction of MTT Assay on Human Lung Epithelial Cancer Cell Lines. J Biosens Bioelectron 2015, 6, 2, doi: 10.4172/2155-6210. 1000170.
- Tat J., Liu M., Wen X.Y.: Zebrafish cancer and metastasis models for in vivo drug discovery. Drug Discov Today Technol 2013, 10, e83–e89, doi: 10.1016/j.ddtec.2012.04.006.
- Teske E., Rutteman G.R., Kirpenstein J., Hirschberger J.: A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. Vet Comp Oncol 2011, 9, 283–289, doi: 10.1111/j.1476-5829.2011. 00266.x.
- Vail D.M., Kravis L.D., Cooley A.J., Chun R., MacEwen E.G.: Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997, 39, 410–416, doi: 10.1007/s002800050591.
- Varankar S.S., Bapat S.A.: Migratory Metrics of Wound Healing: A Quantification Approach for in vitro Scratch Assays. Front Oncol 2018, 8, 1–13, doi: 10.3389/fonc.2018.00633.
- Wang L., Pan T., Wang Y., Yu J., Qu P., Chen Y., Xin H., Wang S., Liu J., Wu Y.: Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms. Molecules 2022, 27, 1–15, doi: 10.3390/molecules 27196201.
- Wilk S.S., Zabielska-Koczywas K.A.: Molecular mechanisms of canine osteosarcoma metastasis. Int J Mol Sci 2021, 22, 3639, doi: 10.3390/ijms22073639.
- Wlodkowic D., Akagi J., Dobrucki J., Errington R., Smith P.J., Takeda K., Darzynkiewicz Z. Kinetic viability assays using DRAQ7 probe. Curr Protoc Cytom 2013, 65, 9.41.1–9.41.8, doi: 10.1002/0471142956.cy0941s65.
- Zabielska-Koczywąs K., Lechowski R.: The use of liposomes and nanoparticles as drug delivery systems to improve cancer treatment in dogs and cats. Molecules 2017, 22, 2167, doi: 10.3390/molecules22122167.
- Zhao M., Ding X.-F., Shen J.-Y., Zhang X.-P., Ding X.-W., Xu B.: Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. J Zhejiang Univ Sci B 2017, 18, 15–26, doi: 10.1631/jzus.B1600303.